Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Aims For Flexibility In Upcoming Drug/Test Co-Development Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed

You may also be interested in...



FDA Plans Guidance This Year On Co-Development Of Diagnostics And Drugs

FDA expects to complete a guidance document on co-development of diagnostics and drugs used for personalized medicine by the end of this year, FDA Commissioner Margaret Hamburg said at a meeting in Washington, D.C., Feb. 25

MedCAC Supports Some PGx Test Regimens, But Calls For Overall Better Data

There is enough strong evidence to show that a select few pharmacogenomic (PGx) tests can be applied in a manner that positively affects patient outcomes, members of a CMS advisory panel concluded Jan. 27

Dx Groups To FDA: Time For Companion Diagnostics Guidance Is Now

Industry groups representing test manufacturers, labs, drug firms and others are redoubling their pressure on FDA to clarify the regulatory requirements for co-development of diagnostics and drug treatments

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT028817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel